Education
About Us
Working with TipRanks
Follow Us
Tourmaline Bio (TRML)
NASDAQ:TRML
TRML Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TRML Stock 12 Month Forecast
Average Price Target
$52.40
▲(136.36% Upside)
| Highest Price Target$65.00 | Average Price Target$52.40 | Lowest Price Target$35.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$50
Buy
125.53%
Upside
Reiterated
08/15/25
Tourmaline Bio's Strategic Advancements and Promising Clinical Trial Results Reinforce Buy RatingOur 12-month price target is derived from an estimated market value of the firm at $1.30B. This includes a discounted cash flow (DCF) analysis-based asset value of $1.04B for pacibekitug, using a 15% discount rate and 2% terminal growth rate, and $256.3M cash. Assigned probability of approval is 35% for pacibekitug in TED. Assuming 25.7M shares outstanding at the end of 2Q26, this yields a value of approximately $50 per share.
Leerink Partners
$54
Buy
143.57%
Upside
Reiterated
08/13/25
LifeSci Capital
$58
Buy
161.61%
Upside
Reiterated
08/13/25
Tourmaline Bio: Strong Financial Position and Promising Cardiovascular Treatment Pipeline Justify Buy RatingThis morning, Tourmaline (Nasdaq: TRML) reported Q2 2025 earnings, finishing the period with $256.4M in cash, cash equivalents and short- term investments, which is expected to fund operaons into the second half of 2027. Recent updates from the Company’s pipeline include: In May, Tourmaline reported topline results from the Phase II TRANQUILITY study, which confirmed pacibekitug’s potenal as a once-quarterly SC injecon for the treatment of CV disease (our note here). The 50mg Q3M dose achieved similar absolute hsCRP reducons and proporon of paents with hsCRP <2mg/L as the go forward doses from Phase II studies with Novo’s zilvekimab (Q4W SC) and CSL’s clazakizumab (Q4W IV), with no meaningful safety signals observed. KOLs connue to highlight that less frequent dosing regimens drive greater adherence, especially in ‘silent’ diseases, which may help improve long-term paent outcomes.
BMO Capital
$35
Buy
57.87%
Upside
Reiterated
07/28/25
Piper Sandler
$65
Buy
193.19%
Upside
Reiterated
07/23/25
Truist Financial
―
Buy
―
Reiterated
05/21/25
TR | OpenAI - 4o
―
Hold
―
Upgraded
05/04/25
Unknown Analyst
GuggenheimNot Ranked
Guggenheim
$55
Buy
148.08%
Upside
Reiterated
05/04/25
Cantor Fitzgerald
―
Buy
―
Reiterated
04/23/25
Chardan Capital
$70
Buy
215.74%
Upside
Initiated
04/22/25
Jefferies
$64
Buy
188.68%
Upside
Reiterated
04/21/25
Wedbush
$42→$43
Buy
93.96%
Upside
Reiterated
03/14/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$50
Buy
125.53%
Upside
Reiterated
08/15/25
Tourmaline Bio's Strategic Advancements and Promising Clinical Trial Results Reinforce Buy RatingOur 12-month price target is derived from an estimated market value of the firm at $1.30B. This includes a discounted cash flow (DCF) analysis-based asset value of $1.04B for pacibekitug, using a 15% discount rate and 2% terminal growth rate, and $256.3M cash. Assigned probability of approval is 35% for pacibekitug in TED. Assuming 25.7M shares outstanding at the end of 2Q26, this yields a value of approximately $50 per share.
Leerink Partners
$54
Buy
143.57%
Upside
Reiterated
08/13/25
LifeSci Capital
$58
Buy
161.61%
Upside
Reiterated
08/13/25
Tourmaline Bio: Strong Financial Position and Promising Cardiovascular Treatment Pipeline Justify Buy RatingThis morning, Tourmaline (Nasdaq: TRML) reported Q2 2025 earnings, finishing the period with $256.4M in cash, cash equivalents and short- term investments, which is expected to fund operaons into the second half of 2027. Recent updates from the Company’s pipeline include: In May, Tourmaline reported topline results from the Phase II TRANQUILITY study, which confirmed pacibekitug’s potenal as a once-quarterly SC injecon for the treatment of CV disease (our note here). The 50mg Q3M dose achieved similar absolute hsCRP reducons and proporon of paents with hsCRP <2mg/L as the go forward doses from Phase II studies with Novo’s zilvekimab (Q4W SC) and CSL’s clazakizumab (Q4W IV), with no meaningful safety signals observed. KOLs connue to highlight that less frequent dosing regimens drive greater adherence, especially in ‘silent’ diseases, which may help improve long-term paent outcomes.
BMO Capital
$35
Buy
57.87%
Upside
Reiterated
07/28/25
Piper Sandler
$65
Buy
193.19%
Upside
Reiterated
07/23/25
Truist Financial
―
Buy
―
Reiterated
05/21/25
TR | OpenAI - 4o
―
Hold
―
Upgraded
05/04/25
Unknown Analyst
GuggenheimNot Ranked
Guggenheim
$55
Buy
148.08%
Upside
Reiterated
05/04/25
Cantor Fitzgerald
―
Buy
―
Reiterated
04/23/25
Chardan Capital
$70
Buy
215.74%
Upside
Initiated
04/22/25
Jefferies
$64
Buy
188.68%
Upside
Reiterated
04/21/25
Wedbush
$42→$43
Buy
93.96%
Upside
Reiterated
03/14/25
Best Analysts Covering Tourmaline Bio
1 Month
xxx
Success Rate
5/8 ratings generated profit
Average Return
+20.44%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +20.44% per trade.
3 Months
xxx
Success Rate
5/8 ratings generated profit
Average Return
+26.44%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +26.44% per trade.
1 Year
Success Rate
8/11 ratings generated profit
Average Return
+24.88%
reiterated a buy rating 3 months ago
Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +24.88% per trade.
2 Years
xxx
Success Rate
8/11 ratings generated profit
Average Return
+31.82%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 72.73% of your transactions generating a profit, with an average return of +31.82% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TRML Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jul 25
Aug 25
Strong Buy
10
13
21
15
14
Buy
2
3
3
2
1
Hold
3
1
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
17
25
17
15
Each month's total comprises the sum of three months' worth of ratings.
TRML Financial Forecast
TRML Stock Forecast FAQ
What is TRML’s average 12-month price target, according to analysts?
Based on analyst ratings, Tourmaline Bio’s 12-month average price target is 52.40.
What is TRML’s upside potential, based on the analysts’ average price target?
Tourmaline Bio has 136.36% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TRML a Buy, Sell or Hold?
Tourmaline Bio has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Tourmaline Bio’s price target?
The average price target for Tourmaline Bio is 52.40. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $65.00 ,the lowest forecast is $35.00. The average price target represents 136.36% Increase from the current price of $22.17.
The highest analyst price target is $65.00 ,the lowest forecast is $35.00. The average price target represents 136.36% Increase from the current price of $22.17.
What do analysts say about Tourmaline Bio?
Tourmaline Bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of TRML?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.